First Patient Dosed in EVICTION Trial Evaluating ImCheck’s Lead Anti-Cancer Drug, ICT01: A Novel Gamma Delta T Cell-Activating Immunotherapy
March 26, 2020 06:00 ET
|
ImCheck Therapeutics SAS
FOR IMMEDIATE RELEASE -- First-in-human, international, multi-center trial to test Butyrophylin 3A-targeted antibody in advanced solid and hematologic tumors -- Marseille, France, March 26, 2020 –...
ImCheck Therapeutics Expands Leadership Team with Appointment of Hans Henrik Chrois Christensen as Chief Financial Officer and Chief Operating Officer
March 17, 2020 06:33 ET
|
ImCheck Therapeutics SAS
-- Mr. Christensen adds financial, strategic and corporate development expertise to the ImCheck team -- Marseille, France, March 17, 2020 – ImCheck Therapeutics announced today the appointment of...
ImCheck Raises $53 Million Series B to Advance Clinical Pipeline of Novel Gamma Delta T-Cell-Focused Antibodies for Cancer and Autoimmune Diseases
December 04, 2019 00:45 ET
|
ImCheck Therapeutics SAS
-- Bpifrance and Pfizer Ventures co-led international investor syndicate -- Marseille, France, December 04, 2019, 6:45 AM CET – ImCheck Therapeutics, a biotech company developing a first-in-class...
ImCheck Therapeutics appoints Paul Frohna MD, PhD, PharmD,as Chief Medical Officer
July 20, 2019 11:00 ET
|
ImCheck Therapeutics SAS
Paul Frohna brings over 15 years of experience in translational medicine and clinical and regulatory strategy Marseille, France, 18 July 2019 – ImCheck Therapeutics, a biotech company on the cutting...
ImCheck Therapeutics lève 20 M€ et recrute son Président
May 02, 2017 11:59 ET
|
ImCheck Therapeutics SAS
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
ImCheck Therapeutics lève 20 M€ et...
ImCheck Therapeutics raises €20 Million and appoints its CEO
May 02, 2017 11:59 ET
|
ImCheck Therapeutics SAS
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
ImCheck Therapeutics raises €20...